Evidence map›Paper›PMID 24632846›Full record

ArticleActa pharmacologica Sinica2014

Ginsenoside Rg1 protects mouse podocytes from aldosterone-induced injury in vitro.

Nan Mao, Yuan Cheng, Xin-li Shi, Li Wang, Ji Wen, Qiong Zhang, Qiong-dan Hu, Jun-ming Fan

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Ginsenoside Rg1 Alleviates Podocyte Injury Induced by Hyperlipidemia via Targeting the mTOR/NF-Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Effect of Tongxinluo on Nephrin Expression via Inhibition of Notch1/Snail Pathway in Diabetic Rats.Evidence-based complementary and alternative medicine : eCAM · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Nan MaoDepartment of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China.
Yuan ChengDepartment of Nephrology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.
Xin-li ShiDepartment of Pathobiology and Immunology, Hebei University of Traditional Chinese Medicine, Shijiazhuang 050200, China.
Li Wang1] The Research Center for Preclinical Medicine, Luzhou Medical College, Luzhou 646000, China [2] State Key Laboratory of Biotherapy of Human Disease, West China Hospital, Sichuan University, Chengdu 610041, China.
Ji WenDepartment of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China.
Qiong ZhangDepartment of Nephrology, The Affiliated Traditional Chinese Medicine Hospital of Luzhou Medical College, Luzhou 646000, China.
Qiong-dan HuDepartment of Nephrology, The Affiliated Traditional Chinese Medicine Hospital of Luzhou Medical College, Luzhou 646000, China.
Jun-ming Fan1] Department of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China [2] Department of Nephrology, The Affiliated Traditional Chinese Medicine Hospital of Luzhou Medical College, Luzhou 646000, China [3] State Key Laboratory of Biotherapy of Human Disease, West China Hospital, Sichuan University, Chengdu 610041, China.
Southwest Medical University · CNWest China Hospital of Sichuan University · CNHebei University of Chinese Medicine · CNShenzhen Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAldosterone is elevated in many diseases such as hypertension, diabetic nephropathy and chronic kidney disease, etc. The aim of this study was to investigate the effects of aldosterone on intracellular ROS production and autophagy in podocytes in vitro, and to explore the possibility of ginsenoside Rg1 (Rg1) being used for protecting podocytes from aldosterone-induced injury.

methodsMPC5 mouse podocyte cells were tested. Autophagosome and autophagic vacuole formation were examined under confocal microscopy with MDC and acridine orange staining, respectively. ROS were detected with flow cytometry. Malondialdehyde content and superoxide dismutase (T-SOD) activity were measured using commercial kits. The expression of LC3-II, beclin-1, SOD2 and catalase was measured by Western blotting.

resultsTreatment with aldosterone (10 nmol/L) significantly increased ROS generation and the expression of SOD2 and catalase in MPC5 cells. Furthermore, treatment with aldosterone significantly increased the conversion of LC3-I to LC3-II, beclin-1 expression and autophagosome formation. Co-treatment with rapamycin (1 ng/mL) or chloroquine (10 μmol/L) further increased aldosterone-induced autophagosome formation. Co-treatment with Rg1 (80 ng/mL) effectively relieved oxidative stress and increased T-SOD activity at the early stage and subsequently decreased autophagy in aldosterone-treated podocytes. Co-treatment with 3-MA (4 mmol/L) or NAC (50 mmol/L) exerted similar effects against aldosterone-induced autophagy in podocytes.

conclusionAldosterone enhances ROS generation and promotes autophagy in podocytes in vitro. Ginsenoside-Rg1 effectively relieves aldosterone-induced oxidative stress, thereby indirectly inhibiting aldosterone-induced podocyte autophagy.

Indexed as

AldosteroneAnimalsAntioxidantsApoptosis Regulatory ProteinsAutophagyBeclin-1CatalaseCell LineCytoprotectionGinsenosidesMalondialdehydeMiceMicrotubule-Associated ProteinsPodocytesReactive Oxygen SpeciesSuperoxide DismutaseAldosteroneAntioxidantsApoptosis Regulatory ProteinsBeclin-1Becn1 protein, mouseCatalaseginsenoside Rg1GinsenosidesMalondialdehydeMap1lc3b protein, mouseMicrotubule-Associated ProteinsReactive Oxygen SpeciesSuperoxide DismutaseSuperoxide Dismutase 2

Identifiers

PMID24632846
PMCPMC4813722
OpenAlexW2008722963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.